RALEIGH, NC – A diabetes candidate is getting a second chance, this time as a treatment for Alzheimer’s disease. DARA BioSciences (Nasdaq: DARA) has licensed away diabetes treatment DB959 — another step toward focusing purely on an oncology platform.
The company has granted Research Triangle Park startup T3D Therapeutics the rights to the candidate.
“This program no longer fits into the strategic focus of Dara,” explains Dara CEO David Drutz.
T3D is very familiar with the compound, as its founder and CEO, John Didsbury, used to be the chief scientific officer at Dara.
But they’re not just looking at it as a treatment for diabetes. Didsbury says he aims to develop it as a “transformational new therapy” to treat Alzheimer’s disease.
“Unlike other therapies in development that target a single pathology, typically the reduction or prevention of beta amyloid plaque buildup, T3D expects DB959 will afford a multidimensional opportunity,” he says.
Basically, as well as focusing on plaque issues, the treatment will follow other aspects of Alzheimer’s as well, such as insulin resistance and neuro-inflammation.
Didsbury says the diabetes market is highly competitive, meaning the candidate might have a better chance of making a difference in central nervous system therapies.